0001801385-24-000007.txt : 20240228 0001801385-24-000007.hdr.sgml : 20240228 20240228213356 ACCESSION NUMBER: 0001801385-24-000007 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240226 FILED AS OF DATE: 20240228 DATE AS OF CHANGE: 20240228 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ROMANO KATHRYN CENTRAL INDEX KEY: 0001801385 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 24698480 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 FORMER NAME: FORMER CONFORMED NAME: Romano Kathryn DATE OF NAME CHANGE: 20200128 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821080209 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 4 1 wk-form4_1709174024.xml FORM 4 X0508 4 2024-02-26 0 0001711279 Krystal Biotech, Inc. KRYS 0001801385 ROMANO KATHRYN C/O KRYSTAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701 PITTSBURGH PA 15203 0 1 0 0 Chief Accounting Officer 1 Common Stock 2024-02-26 4 M 0 5000 52.26 A 17556 D Common Stock 2024-02-26 4 S 0 5000 135 D 12556 D Common Stock 2024-02-26 4 M 0 3087 52.26 A 15643 D Common Stock 2024-02-26 4 S 0 3087 140 D 12556 D Common Stock 2024-02-26 4 F 0 1533 157 D 11023 D Common Stock 2024-02-27 4 M 0 1913 52.26 A 12936 D Stock Option (Right to Buy) 52.26 2024-02-26 2024-02-26 4 M 0 5000 0 D 2030-01-30 Common Stock 5000 5000 D Stock Option (Right to Buy) 52.26 2024-02-26 2024-02-26 4 M 0 3087 0 D 2030-01-30 Common Stock 3087 1913 D Stock Option (Right to Buy) 52.26 2024-02-27 2024-02-27 4 M 0 1913 0 D 2030-01-30 Common Stock 1913 0 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 5,000 shares with a limit price of $135.00 per share. The transaction was executed in multiple trades at the same sale price. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and sales of 3,087 shares with a limit price of $140.00 per share. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,900 shares of restricted stock on February 26, 2024. The closing price on February 26, 2024 of the Company's common stock on NASDAQ. The option exercise reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on August 29, 2023 and will terminate on June 28, 2024 and contemplates option exercises and holding 1,913 shares with a prior closing price from $135.00 per share. 50,000 options were granted that vest in four equal annual installments beginning on January 20, 2021. /s/ Kathryn Romano 2024-02-28